WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 1271% more annual revenue ($60.96B vs $4.45B). IDXX leads profitability with a 24.6% profit margin vs 11.9%. BUD appears more attractively valued with a PEG of 1.78. IDXX earns a higher WallStSmart Score of 63/100 (C+).

BUD

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.7Quality: 5.0

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 2.7Quality: 5.0
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDOvervalued (-9.4%)

Margin of Safety

-9.4%

Fair Value

$70.63

Current Price

$79.89

$9.26 premium

UndervaluedFair: $70.63Overvalued
IDXXSignificantly Overvalued (-41.2%)

Margin of Safety

-41.2%

Fair Value

$459.52

Current Price

$560.11

$100.59 premium

UndervaluedFair: $459.52Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD3 strengths · Avg: 8.3/10
Market CapQuality
$159.00B9/10

Large-cap with strong market position

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

EPS GrowthGrowth
20.3%8/10

Earnings expanding 20.3% YoY

IDXX3 strengths · Avg: 9.7/10
Return on EquityProfitability
72.9%10/10

Every $100 of equity generates 73 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

Price/BookValuation
10.7x4/10

Trading at 10.7x book value

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
4.032/10

Expensive relative to growth rate

P/E RatioValuation
42.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
27.8x2/10

Trading at 27.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 42.0x leaves little room for execution misses.

Key Dynamics to Monitor

BUD profiles as a value stock while IDXX is a mature play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.57 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BUD scores higher overall (63/100 vs 63/100) and 12.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?